Clinical effectiveness of pneumococcal vaccination against acute myocardial infarction and stroke in people over 60 years: the CAPAMIS study, one-year follow-up Angel Vila-Corcoles, Olga Ochoa-Gondar, Teresa Rodriguez-Blanco, Antonia Gutierrez-Perez, Angel Vila-Rovira, Frederic Gomez, Xavier Raga, Cinta de Diego, Eva Satue, Elisabet Salsench and Epivac Study Group, March 22, 2012.

Conflicting results have been recently reported evaluating the relationship between pneumococcal vaccination and the risk of thrombotic vascular events. This study assessed the clinical effectiveness of the 23-valent polysaccharide pneumococcal vaccine (PPV23) against acute myocardial infarction and ischaemic stroke in older adults.


Population-based prospective cohort study conducted from December 1, 2008 until November 30, 2009, including all individuals [greater than or equal to] 60 years-old assigned to nine Primary Care Centres in Tarragona, Spain (N = 27,204 individuals). Primary outcomes were hospitalisation for acute myocardial infarction and/or ischaemic stroke. All cases were validated by checking clinical records. The association between pneumococcal vaccination and the risk of each outcome was evaluated by Multivariable Cox proportional-hazard models (adjusted by age, sex, influenza vaccine status, presence of comorbidities and cardiovascular risk factors). Read More